BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lapa D, Garbuglia AR, Capobianchi MR, Del Porto P. Hepatitis C Virus Genetic Variability, Human Immune Response, and Genome Polymorphisms: Which Is the Interplay? Cells 2019;8:E305. [PMID: 30987134 DOI: 10.3390/cells8040305] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Sepulveda-Crespo D, Resino S, Martinez I. Innate Immune Response against Hepatitis C Virus: Targets for Vaccine Adjuvants. Vaccines (Basel) 2020;8:E313. [PMID: 32560440 DOI: 10.3390/vaccines8020313] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
2 Xu Y, Zhang Z, Shi J, Liu X, Tang W. Recent developments of synthesis and biological activity of sultone scaffolds in medicinal chemistry. Arabian Journal of Chemistry 2021;14:103037. [DOI: 10.1016/j.arabjc.2021.103037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Marascio N, Mazzitelli M, Pavia G, Giancotti A, Barreca GS, Costa C, Pisani V, Greco G, Serapide F, Trecarichi EM, Casalinuovo F, Liberto MC, Matera G, Torti C. Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4. Cells. 2019;8. [PMID: 31060315 DOI: 10.3390/cells8050416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Grzegorzewska AE, Mostowska A, Świderska MK, Marcinkowski W, Stolarek I, Figlerowicz M, Jagodziński PP. Polymorphism rs368234815 of interferon lambda 4 gene and spontaneous clearance of hepatitis C virus in haemodialysis patients: a case-control study. BMC Infect Dis 2021;21:102. [PMID: 33482747 DOI: 10.1186/s12879-021-05777-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Keikha M, Eslami M, Yousefi B, Ali-Hassanzadeh M, Kamali A, Yousefi M, Karbalaei M. HCV genotypes and their determinative role in hepatitis C treatment. Virusdisease 2020;31:235-40. [PMID: 32904762 DOI: 10.1007/s13337-020-00592-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Alkharsah KR, Alzahrani AJ, Obeid OE, Aljindan RY, Guella A, Al-Ali AK, Al-Turaifi HR, Sallam TA. Association between Hepatitis C Virus Viremia and the rs12979860, rs2228145 and rs1800795 SNP (CT/AC/GG) Genotype in Saudi Kidney Transplant Recipients. Saudi J Med Med Sci 2020;8:46-52. [PMID: 31929778 DOI: 10.4103/sjmms.sjmms_175_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Zhang J, Chen N, Chen Z, Liu Y, Zheng K, Qiu Y, Zhang N, Zhu J, Yu H, He Q. Low Mannose Binding Lectin, but Not L-Ficolin, Is Associated With Spontaneous Clearance of Hepatitis C Virus After Infection. Front Immunol 2020;11:587669. [PMID: 33262767 DOI: 10.3389/fimmu.2020.587669] [Reference Citation Analysis]
8 Guest JD, Wang R, Elkholy KH, Chagas A, Chao KL, Cleveland TE 4th, Kim YC, Keck ZY, Marin A, Yunus AS, Mariuzza RA, Andrianov AK, Toth EA, Foung SKH, Pierce BG, Fuerst TR. Design of a native-like secreted form of the hepatitis C virus E1E2 heterodimer. Proc Natl Acad Sci U S A 2021;118:e2015149118. [PMID: 33431677 DOI: 10.1073/pnas.2015149118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
9 Kennedy RB, Ovsyannikova IG, Palese P, Poland GA. Current Challenges in Vaccinology. Front Immunol. 2020;11:1181. [PMID: 32670279 DOI: 10.3389/fimmu.2020.01181] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
10 Pinto RB, Ramos ARL, Padua LT, Swayze EJ, Cambou MC, Fiorini M, Melo M, Santos BR, Canti ICT, Silveira MLR, Solari MIG, de Correa JF, Chew K, Dos Santos Varella IR, Nielsen-Saines K. Prospective cohort study of children exposed to hepatitis C virus through a pregnancy screening program. Int J Infect Dis 2021;110:62-8. [PMID: 34273517 DOI: 10.1016/j.ijid.2021.07.019] [Reference Citation Analysis]
11 Mosa AI. Implications of viral transmitted/founder (T/F) dynamics on vaccine development. Hum Vaccin Immunother 2021;17:2293-7. [PMID: 33377822 DOI: 10.1080/21645515.2020.1861878] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Wang R, Suzuki S, Guest JD, Heller B, Almeda M, Andrianov AK, Marin A, Mariuzza RA, Keck ZY, Foung SKH, Yunus AS, Pierce BG, Toth EA, Ploss A, Fuerst TR. Induction of broadly neutralizing antibodies using a secreted form of the hepatitis C virus E1E2 heterodimer as a vaccine candidate. Proc Natl Acad Sci U S A 2022;119:e2112008119. [PMID: 35263223 DOI: 10.1073/pnas.2112008119] [Reference Citation Analysis]
13 Kishta S, Tabll A, Omanovic Kolaric T, Smolic R, Smolic M. Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals. Biomedicines 2020;8:E175. [PMID: 32630610 DOI: 10.3390/biomedicines8060175] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Kishta S, Tabll A, Omanovic Kolaric T, Smolic R, Smolic M. Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals. Biomedicines 2020;8:E175. [PMID: 32630610 DOI: 10.3390/biomedicines8060175] [Reference Citation Analysis]